Professor Philip Routledge, BPS President, Chair
Phil's postgraduate training in clinical pharmacology took place in the Department of Pharmacology/Clinical Pharmacology in Newcastle University (supervised by Sir Mike Rawlins) and Vanderbilt and Duke Universities in the USA. His main interests are in pharmacovigilance and in methods to promote safe and effective prescribing.
Professor Humphrey Rang, President-Elect
Humphrey was a J H Burn research Fellow, at the Department of Pharmacology, Oxford, under the supervision of WDM Paton. His research interests are drug receptors, including the first successful receptor labelling studies, and kinetic analysis of ligand binding. Ion channels, channel block and synaptic mechanisms at the neuromuscular junction and autonomic ganglia. Pain, nociception and the identification of new targets for analgesic drugs. Humphrey has authored many research papers on these topics. Humphrey is also an author of Pharmacology (1987) now in 7th Edition, translated into 10 languages. Winner of BMA Student Textbook Award, 2007).
Drug Discovery (2006). Winner of RSM book prize, 2007.
Dr Robin Hiley, Honorary Treasurer
Robin trained under the supervision of Sir Arnold Burgen, first in Cambridge and then at the National Institute for Medical Research. He was a lecturer at the University of Liverpool before moving back to the University of Cambridge where he is now Reader in Vascular Pharmacology. His interests lie in the control of blood vessel tone by the endothelium and in the effects of lipid derivatives, such as the endocannabinoids, on cardiovascular function.
Professor Ian Kitchen, Co-Chair of CHOPT
Ian gained his Ph.D. in Pharmacology from Chelsea College and has held academic positions at the London Hospital Medical College and the University of Surrey, where he is currently Associate Dean for Research & Enterprise in the Faculty of Health and Medical Sciences. As Professor of Neuropharmacology his main research interests are in the opioid field, with most recent focus on addiction neurobiology. He is founder and President of the European Opioid Conference.
Professor Donald Singer, Co-Chair of CHOPT
Donald is Professor of Clinical Pharmacology and Therapeutics at the University of Warwick's graduate medical school, where he was founding head of Clinical Sciences. He studied medicine in Aberdeen and carried out MD research and clinical pharmacology training in London. His interests include new chemical and genomic approaches to personalising medicine, prevention and treatment of cardiovascular disorders, and public understanding of health.
Professor Helen Cox, Elected Trustee
Helen is Professor of Pharmacology at King's College London and since her PhD at University of Southampton and postdoctoral research at University of Cambridge, she has been interested in peptide receptor signalling. Her current research focuses on how the intestine senses nutrients and signals their presence logically to alter gut function, and acts as an interface that regulates energy homeostasis. Helen has served on the Editorial Board of the BJP, on BPS Finance & Executive committees.
Dr Michael Seed, Elected Trustee
Mike trained as a pharmacologist at the University of Bath, and his PhD under the supervision of Ivor Williams. He joined the field of arthritis drug discovery, working on integrative arthritis and angiogenesis modelling at Hoechst and then Roussel. He continued his research into the modelling of angiogenesis, inflammation, immunity and arthritis at the William Harvey Research Institute, in collaboration with Biotech and a variety of drug targets. He has been lecturing on the Bart’s & the London MBBS and BMedSci courses, and is currently Senior Lecturer in Pharmacology at the University of East London.
Dr Smita Price, Elected Trustee (Industry)
Smita is a neuropharmacologist with 20 years’ experience of working in the pharmaceutical industry. Smita obtained her BSc in Pharmacology at Cardiff University and gained her PhD in Physiology studying Movement disorders at Manchester University (supervised by Dr Paul Slater and Dr Alan Crossman). She spent 5 years as a Post-Doctoral fellow at the Institute of Psychiatry in London, specialising in epilepsy and schizophrenia. Smita then joined Merck Neuroscience Research centre in Harlow, where she gained over 15 years’ experience in CNS drug discovery and development. Smita is currently an independent pharmaceutical consultant.
Dr David Wood, Elected Trustee (Clinical)
David is a Consultant Physician and Clinical Toxicologist at Guy's and St Thomas' NHS Foundation Trust and King's Health Partners and an honorary senior lecture at King's College London. He studied medicine at the University of Bristol and his MD research and training in clinical pharmacology and therapeutics, clinical toxicology and general medicine in London. He has specialist clinical, research and academic interests in the epidemiology of use and acute toxicity ('harm') associated with the use of classical recreational drugs and novel psyschoactive substances ('legal highs'); he is an expert adviser to both the UK Advisory Council on the Misuse of Drugs (ACMD) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in these areas.
Professor Ann Daly, Co-opted Trustee
Ann is Professor of Pharmacogenetics at the Institute of Cellular Medicine, Newcastle University. After a PhD in Biochemical Pharmacology at Trinity College, Dublin and postdoctoral work at the University of Geneva, she joined the Newcastle University Pharmacogenetics Research Group. Her research interests include the pharmacogenetics of the human cytochromes P450 and genetic susceptibility to idiosyncratic adverse drug reactions.
Dr Christine Williams, Co-opted Trustee
Chris studied for her PhD with Professor Philip Strange and Dr Barrie Rooney at the University of Kent at Canterbury (UK) between 1991 and 1994, where she investigated the expression of dopamine receptors using the baculovirus system. Subsequently she joined the molecular pharmacology team at Pfizer supporting exploratory efforts for the Neuroscience group. After 3 years in this team, she moved in to the high-throughput screening arena and over the proceeding 10 years increased her expertise and responsibility in this field, leading to her appointment as director of the Sandwich Global HTS CoE team in 2005. In this role she was responsible for the prosecution of all HTS targets derived from the Pfizer research sites. In 2009, she decided to move into a business manager role at Pfizer, supporting the Head of the Global Research Centres of Emphasis (RCoEs), where she is responsible for ensuring that the many & diverse functions provided by the individual RCoE teams add value to internal and external partners.
David O Douglas, Trustee
David is a Chartered Accountant who has over 40 years experience with charities as a trustee, treasurer, adviser and auditor. Charities (including member societies) are being encouraged to include people with specialist experience in their Board of Trustees. David has had an involvement with the Society in various capacities over the last 30 years which we feel will be of benefit to us.